Comparison of body weights of 4 experimental groups on day 20 after inoculation. Body weights graph corresponds to Fig. 5A-D.

SF1: NDRG1 silencing upregulates GSK3β expression and cell growth signaling pathways; SF2: NDRG1 overexpression suppresses cell growth, GSK3β expression and cell growth signaling pathways; SF3: Effect of WT and Î"6 deletion mutant of NDRG1 on cell growth and cell growth signaling pathway in U251 cells; SF4: DIF-1 suppresses GBM cell growth accompanied with enhanced expression of NDRG1 and decreased expression of GSK3β; SF5: DIF-1 suppressed GBM cell growth by enhancing NDRG1 expression and decreasing GSK3β expression; SF6: Measurement of the DIF-1 concentration in mouse plasma and brain; SF7: DIF-1 suppresses tumor growth by U87MG cells in orthotopic therapeutic models; SF8: NDRG1 mRNA expression level does not predict overall survival of patients with GBM.

Supplementary Figure S1. Effect of YBX1 on ESR protein expression and ubiquitination of ESR. Supplementary Figure S2. Effect of ESR knockdown on ERBB2 expression.

PDF - 82K, Supplementary materials and methods.

PDF - 163K, A, Establishment of stable integrinβ1-overexpressing cell lines (PC9/ITG2 and PC9/ITG11) or control cDNA transfected cell line (PC9/Mock) from PC9 cells by transfection with integrinβ1 cDNA. B, The effect of integrinβ1 overexpression on erlotinib sensitivity. Transfectants were treated with erlotinib for 3 days, and the IC50 values (μM) for erlotinib were 0.04 (PC9/Mock), 0.09 (PC9/ITG2), and 0.10 (PC9/ITG11). C, Western blots showing the expression and phosphorylation of EGFR, integrinβ1, Akt, and Erk1/2 following exposure to erlotinib for 5 hr.

PDF- 199K, A, Heterodimerization of integrinα2 or α5 with integrinβ1. B, Effects of integrinβ1, α2, or α5 siRNA, with or without erlotinib treatment, on downstream signaling molecules in PC9/ER2-2 cells.

The effect of everolimus on expression and phosphorylation of YBX1, ERK/p90RSK and AKT/mTOR signaling molecules in six TNBC cell lines.

PDF File - 66K, Sensitivity to lapatinib, erlotinib, SU11274, cisplatin and CPT-11 in human gastric cancer cell lines.

PDF - 133K, A, PC9 and PC9/ER2-2 cells were exposed to 1 μM erlotinib with or without 0.1 μM dasatinib for 5 hr. B, The sensitivity to dasatinib after exposure for 3 days was determined by proliferation assay.

<p>PDF - 76K, Summary of expression states of integrins and resistance-related molecules in EGFR-TKI sensitive and refractory tumors.</p>

Supplementary Figure Legends and Methods

PDF - 83K, Supplementary figure legends.

YBX1 and pYBX1 (S102) expression of 397 invasive breast cancer patients obtained from TCGA (Breast Invasive Carcinoma (TCGA, Provisional).

Expression of YBX1, pYBX1 and downstream molecules in 6 human breast cancer cell lines.

<p>ST1:Clinical characteristics of 28 patients with GBM, from whom tumor samples are analyzed.</p>

<p>Supplementary materials and methods</p>

Supplementary Materials and Methods

PDF - 76K, Summary of expression states of integrins and resistance-related molecules in EGFR-TKI sensitive and refractory tumors.

IC50 values of fulvestrant, everolimus, AZD8055 and U0126 in ER(+)/HER2(-) and ER(-)/HER2(+) human breast cancer cell lines.

Overview of pathological diagnosis and treatment status of patients refractory to endocrine therapeutics.